How Investors Are Reacting To Eisai (TSE:4523) Leaning On Leqembi After Fresh Sales Update
- Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s drug Leqembi, underscoring the scale of its neurology operations.
- This combination of strong Leqembi revenue and fresh quarterly sales data highlights how Eisai’s neuroscience focus is increasingly anchored by a single high-impact Alzheimer’s therapy.
- Next, we’ll examine how Leqembi’s ¥88 billion revenue contribution and the latest quarterly sales update reshape Eisai’s investment narrative.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Eisai Investment Narrative Recap
To own Eisai today, you need to believe its bet on neurology, and especially Alzheimer’s, will justify a premium price tag despite recent earnings pressure and pricing risks. The preliminary first quarter 2026 sales of ¥26.2 billion, combined with Leqembi’s FY2025 revenue of ¥88.0 billion, reinforce how central this single drug has become to the story, but do not materially change the near term catalyst around subcutaneous Leqembi uptake or the key risk of concentrated exposure.
Among recent announcements, the US FDA’s acceptance of the supplemental BLA for Leqembi’s IQLIK subcutaneous autoinjector, with a PDUFA target of May 24, 2026, looks most relevant. If approved, it could accelerate the shift to at home dosing and potentially influence how investors interpret the latest Leqembi revenue run rate, since convenience and adherence are central to the bullish catalyst around broader adoption.
Yet beneath this progress, investors should also be aware of pricing pressure risks that could…
Read the full narrative on Eisai (it’s free!)
Eisai’s narrative projects ¥938.2 billion revenue and ¥74.9 billion earnings by 2029.
Uncover how Eisai’s forecasts yield a ¥5009 fair value, a 7% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about ¥1,017.8 billion by 2029, so this new Leqembi update may either reinforce that upbeat view or prompt a rethink, especially if you compare it with concerns about future price cuts and how quickly at home regimens might really scale.
Explore 2 other fair value estimates on Eisai – why the stock might be worth just ¥5009!
Decide For Yourself
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Searching For A Fresh Perspective?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Eisai might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
